COVID-19: Life in the time of coronavirus

Article

Carl Awh, MD,  explains offers insight on the changes his practice (Tennessee Retina in Nashville, Tennessee), has implemented for the sake of staff/patients' health, as well as the safety precautions he and his staff are taking on a daily basis amid the coronavirus pandemic.

 

See more coronavirus coverage

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A phone with the US Food and Drug Administration (FDA) logo on the screen. Image credit: ©gguy – stock.adobe.com

US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2

Martin David Harp;Hattie Hayes
March 6th 2025
Article

The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Two illustrated DNA helices on a blue background. Image credit: ©rost9 – stock.adobe.com

EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST

Hattie Hayes
March 4th 2025
Article

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease

An illustration of an eye's iris and pupil, suspended on a dark background which evokes the depth of outer space. Image credit: ©Enis – stock.adobe.com

Novel stem cell therapy restores corneal damage previously believed irreversible

Lynda Charters
March 4th 2025
Article

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

An image showing the degeneration of neuron cells. Image credit: ©Corona Borealis – stock.adobe.com

Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD

Jordana Joy
March 3rd 2025
Article

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

Dozens of cigarette butts, stubbed out on the dirty ground. Image credit: ©Gagula – stock.adobe.com

Study: cigarette smoking negatively affects choroidal vascularity

Lynda Charters
March 3rd 2025
Article

The investigators' findings suggest that CVI is a valuable noninvasive predictive biomarker for monitoring vascular changes in patients who smoke

© 2025 MJH Life Sciences

All rights reserved.